Alpha Tau Medical Ltd.
DRTSHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the. With a market capitalization of $873.0M, it sits in small-cap territory. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Market Cap
$873.0M
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-19.38
EPS (TTM)
$-0.67
EPS (Fwd)
$-0.50
ROE
-90.5%
ROA
-30.5%
Cash
$76.4M
Total Debt
$14.3M
Free CF
—
52W Change
222.2%
Annual Financials
Cash vs Debt
With $76.4M in cash and $14.3M in debt, DRTS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. ROE of -90.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, DRTS has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing DRTS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.